Introduction
Mature B-cell neoplasms account for 90% of all lymphomas globally and are divided into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) (1) . HL is one of the most common lymphomas in the developed world and comprises two entities, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and classical Hodgkin lymphoma (cHL), which account for <5% and >95% of cases, respectively. The The aetiology of both HL and NHL is still unclear. However, current evidence suggests that environmental exposures, infectious agents, and both immunosuppression and immune activation contribute to the development of these diseases. In addition, as described below, there is compelling evidence for inherited susceptibility to HL and NHL. The search for genetic risk factors has highlighted the importance of the human leukocyte antigen (HLA) region (2, 3) . A crucial role for HLA in disease pathogenesis is further suggested by observations that HLA class I and class II expression is frequently down-regulated in tumour tissue (4, 5) . Taken together, the data implicate HLA-mediated interactions in the pathogenesis of both HL and NHL. This review aims to summarise the main findings that have emerged from HLA association studies and genome-wide association studies (GWAS) of HL and the three most common forms of NHL, namely DLBCL, FL and CLL/SLL.
Evidence for inherited susceptibility in lymphoma
Inherited susceptibility to HL and NHL is supported by several strands of evidence.
First, the incidence of HL and NHL varies significantly between racial and ethnic groups with the Asian population showing one of the lowest incidence rates for both diseases (6) (7) (8) . Population-based studies in the USA demonstrate that the incidence of HL and CLL is consistently low in Asian groups relative to US Whites, suggesting some genetic protection against disease, given similar environmental exposures (6, 8) . Secondly, there is clear evidence of familial aggregation of both HL and NHL.
Studies of HL indicate a 3-9 fold increased risk of HL in first-degree relatives of index cases (9) (10) (11) (12) .
Furthermore, a study of monozygotic and dizygotic twins demonstrated that the co-twin of a monozygotic HL case has a 100-fold increased risk of developing the disease (13) . The Swedish Family Cancer database estimated the heritability of HL in the white population as 28.4% (14) . Individual case-control studies as well as a recent meta-analysis of NHL subtypes also show an increased incidence of DLBCL, FL and CLL in patients with a family history of NHL, with CLL showing the greatest increase of 8-fold (15) (16) (17) (18) (19) (20) (21) . Familial aggregation of CLL cases has also been documented in over 100 familial studies (reviewed in 22) .
Collectively, the data support a genetic predisposition to the development of lymphoma. The highly polymorphic HLA genes are contained within the HLA complex, the human equivalent of the major histocompatibility complex, which is located on the short arm of chromosome 6 and divided into three regions. The class I region contains genes for the α-chains of HLA-A, B and C and also the three non-classical 24) . Polymorphisms in HLA genes lead to amino acid variation within these pockets, and this in turn affects peptide binding preferences; however, products of different HLA alleles can contain identical anchoring pockets thus enabling grouping of HLA alleles into supertypes on the basis of overlapping peptide specificities (25) .
Human Leukocyte Antigens and Genes
To enable an efficient immune response, HLA molecules must bind a peptide and the T-cell repertoire must include clones that recognise the HLA-peptide combination. Absence of either may render an individual susceptible to a given disease.
HLA association studies: caveats and pitfalls
The analysis of HLA associations with disease is challenging and a number of factors need to be taken into consideration. First, study design and sample size are critical but for reasons of practicality are seldom ideal. In case-control studies, spurious results can arise from poor matching between cases and controls, diagnostic misclassification and disease heterogeneity, biased case selection, and retrospective ascertainment of cases leading to survival bias. Population stratification, resulting from admixture of populations with different ancestry, is a particular problem in genetic association studies. Family-based designs aim to avoid the potential confounding effects of population stratification by using parents or unaffected siblings as controls for the index case. However, family-based studies are often limited by size. Small studies frequently report strong associations that disappear or become weak when sample size increases. Sample size is also crucial in case-control studies. To have 80% power to detect a significant association (p<0.05) with an allele with a carrier frequency of 0.10 with an odds ratio of 2 requires >300 cases; following correction for multiple testing of e.g. 50 alleles, this number increases to >600. Thus, most published studies of HLA associations are under-powered to detect small effects sizes and associations with rare alleles. The necessary larger-sized studies are usually limited by cost and sample availability.
Secondly, it is often assumed that the genotyped locus confers susceptibility/protection from disease development. However, the genotyped locus may not be causal but rather may be in linkage disequilibrium (LD) with the causal variant. This is a particular challenge in HLA association studies as there is extensive LD within the HLA complex and many alleles are inherited in a block.
Thus, unadjusted analyses frequently show associations with multiple alleles on the same haplotype; this is less of problem with DP genes as there is a recombination hotspot between DQ and DP. R 2 and D' values are used to describe the extent of LD between two genetic variants. R 2 is a measure of correlation, and high values (>0.8) occur when two alleles are present at equal frequency and inherited together;
an r 2 of 1 indicates that only two of the four possible haplotypes are present. For tagging studies, where one marker is used to tag or substitute for another, r 2 is the important measure; however, in population genetics D', a measure of recombination events between two markers which is not dependent on allele frequency, is generally more informative. A high D' value indicates that the rarer allele is always inherited with the other allele or, in the case of single nucleotide polymorphisms (SNPs), with one of the alleles; r-squared is usually lower since most of the time the commoner allele is present without the rarer allele.
Most HLA association studies describe the frequency of a particular allele (or genotype or phenotype) according to case-control status, with unadjusted statistical analyses, i.e. not adjusted for the effects of other alleles. In order to identify potential causal alleles, various statistical methods have been used to adjust for effects of LD;
although generally more informative, this can complicate comparisons between studies.
Thirdly, the methodology used to type HLA alleles has changed dramatically over the Broad specificities are sometimes further divided into 'split specificities'. With the introduction of molecular typing the naming system was altered and allele designations now include up to four fields separated by colons. The first field contains an asterisk to denote molecular typing and defines the allele of the gene, which often but not always corresponds to the serotype; the second field defines the subtype of the allele. Early HLA association studies generally reported only the first field of the descriptor with more recent, higher resolution studies reporting the first two fields. In describing reported HLA associations we have attempted to adhere to the nomenclature used in the individual studies.
Hodgkin lymphoma
A distinguishing feature of HL, shared by both NLPHL and cHL, is the paucity of malignant cells within the tumour mass, which is largely composed of an inflammatory infiltrate (26) . Until 2001, HL was classified as a single disease, Hodgkin's disease, with four histological subtypes. Following the acceptance that
Hodgkin's disease is a B-cell derived lymphoma and that lymphocyte predominance
Hodgkin's disease has many distinctive features, the disease was renamed HL and separated into two main entities, NLPHL and cHL (27) . Based upon the infiltrate composition and architecture and the morphology of the Hodgkin and Reed-Sternberg (HRS) cells, cHL is now further subdivided into four histological subtypes.
The nodular sclerosis (NSHL) subtype is the most common, accounting for up to 80% of cases, whilst the mixed cellularity (MCHL) subtype accounts for around 15%.
In the late 1980s it was recognized that a proportion of cHL cases, in developed countries, are associated with the EBV (EBV+cHL) and can be distinguished from EBV-negative (EBV-cHL) cases by the presence of the virus within HRS cells (28, 29) . EBV association rates differ by cHL subtype, age, gender and geography reflecting the complexity of the disease (7, 30, 31) . Many HLA association studies were performed before the WHO classification system was introduced and before it was appreciated that EBV was aetiologically associated with a subgroup of cases.
Since most MCHL, but only a minority of NSHL, cases are EBV-positive, MCHL histology and EBV-positivity are frequently used as proxies for each other; although this can help interpretation, it is important to note that at least half of all EBV+cHL cases are of NSHL subtype (our unpublished results).
Early HLA association studies in Hodgkin lymphoma
HL was the first disease for which any HLA association was described (32) . Using 45 sera from multiparous women, Amiel et al (1967) reported an increase in frequency of the 'Payne-Bodmer 4c' antigen from 23% in healthy controls to 51% in HL cases from France. A similar analysis of Dutch cases failed to confirm these results (33) . However, the results were corroborated in 1970 in Australia by Forbes et al (1970) who demonstrated an increased frequency of the 4c antigen and further showed that this resulted from an increased frequency of W5, one of the two specificities recognised by the 4c antibody (34) . Forbes et al (1970) also showed that W5 was less common in females with NSHL and more common in females with MCHL. The 4c specificities were subsequently shown to include HLA-B5, B15, B18
and Bw35 (W5) antigens (35) .
Subsequent investigations using serological typing methods demonstrated an
increased frequency of HLA-B5, B8, B18 and HLA-A1 subtypes in HL patients (Table   1 ) (36) (37) (38) (39) (40) (41) (42) (43) (44) . The strongest association was shown for HLA-A1 with a 6-fold increase in risk of developing cHL (42) . Despite the well-documented linkage between HLA-A1 and B8 antigens, HLA-B8 did not always show a similar increase (39, 43) .
Kissmeyer-Nielson et al (1975) also demonstrated an increased HLA-A1 and A8
prevalence in MCHL cases compared to NSHL and NLPHL cases (39), suggesting subtype-specific HLA associations. Larger, case-control studies further corroborated the association with HLA-A1 and identified a lower prevalence of HLA-A3 and A11 alleles in HL cases compared to healthy controls, suggesting a potential protective effect (Table 1) (35, 36, 45) .
Concurrent family-based studies provided some support for these findings. Marshall et al (1977) investigated seven cases of HL within one family and found no HLA haplotype or allele associated with HL development, although HLA-B8 was detected more often in first-degree relatives of cases (46) . Further studies demonstrated an increased prevalence of HLA-B18, B35, and B37 in cases within families (47, 48) .
Using a shared versus non-shared HLA approach for sibling pairs, a greater than expected HLA identity between siblings with HL was documented (43); however, previously reported allele associations were not detected in this study. Similar haplotype concordance was observed between HL-affected siblings in a study of 16 families where half the families displayed the HLA-A*01-B*08 haplotype (49) .
Investigation of associations with class II alleles lagged behind those of class I alleles due to a lack of appropriate reagents. The earliest observations arose from family studies. In a study of four siblings with HL, HLA typing revealed that all carried the HLA-DR5 antigen (HLA-DR*11 and DR*12 gene products) and two were also HLA-A1-positive (50) . With no obvious differences in EBV antibody titres, chromosomal abnormalities or exposure histories, it was concluded that genetic factors were more important than environmental factors in disease pathogenesis.
Interestingly, some of the earlier studies performed at a time with much higher mortality from HL also observed a survival advantage in association with particular HLA class I types (41, 42, 44, 45, 51) . An increased frequency of HLA-A28 and A8
was observed in HL patients with greater than 15 years and 5 years survival, respectively (41, 44, 45) . Although HLA-A1 was associated with increased disease risk, it was also associated with improved survival and treatment response (42) .
Patients positive for HLA-Aw19 (HLA-A29, 30, 31, 32, 33 gene products) and B5
antigens also had a poorer prognosis (51) .
HLA and HL in the era of molecular typing
Following the introduction of molecular typing methods, attention shifted to HLA class II. Case-control studies demonstrated an increased frequency of HLA-DPB1*03:01 in white patients, with a relative risk of 1.95 (p < 0.01) in the largest study ( These markers are in LD with HLA-A*01 and HLA-A*02 alleles and subsequent studies provided evidence that HLA-A*01:01 is associated with an increased and A*02:01 with a decreased risk of EBV+cHL (60, 61) . The effects of these two alleles are independent and result in A*01:01 and A*02:01 homozygotes having an almost 10-fold difference in odds of developing EBV+cHL (62) . The only GWAS to include cases typed by EBV status in the discovery analysis (63) , identified independent associations between two HLA class I SNPs (rs2734986 and rs6904029) and
EBV+cHL; the effects of these SNPs could be accounted for by the effects of A*01 and A*02 alleles (63) . Thus, several lines of evidence suggest associations between EBV+cHL and these alleles, at least in white populations ( disease risk, suggesting that these alleles could have protective effects; interestingly, this association between DRB1*15:01 and EBV+cHL is in the opposite direction from that described below for EBV-cHL.
Analyses of associations with EBV-cHL are more difficult to interpret, largely due to issues with LD. Although only a small number of studies have stratified cases by EBV status, EBV-cHL cases constitute the majority of cHL cases in industrialised countries, are mainly NSHL, and usually occur in the young adult age group.
Studies of NSHL and of young adult cHL are therefore likely to reflect associations with EBV-cHL (and vice versa). Taken together, such studies provide compelling evidence that DRB1*15:01, DQA1*01:02 and DQB1*06:02, three alleles that are in LD, are associated with an increased risk of EBV-cHL (55, 59, 65, 66) . More recent studies have shown an association between DRB1*07 and decreased risk of EBV-cHL (65, 66). However, as described below, it is not clear whether these alleles are biologically important or whether they are simply tagging another gene(s) or regulatory sequence that is critical in disease pathogenesis.
GWAS have consistently shown that the HLA class II SNP rs6903608, located ~15kb centromeric to DRA, is the variant most strongly associated with cHL (Table 3) CLL/SLL is the third most common accounting for around 12% of cases (79) .
Although immune suppression and autoimmune disorders have been identified as risk factors for NHL, host characteristics also clearly play a role in this disease and its various subtypes (80) .
Similar to cHL, HLA is implicated in NHL susceptibility with early studies showing down-regulation of the expression of HLA class II antigens (81) . Several small studies have reported links between HLA class II alleles and NHL with conflicting results that may be attributable to small sample size, the combined analysis of various NHL subtypes, and/or analysis of different ethnic groups (82) (83) (84) . In contrast, recent analyses of individual subtypes provide more consistent results.
Diffuse Large B-Cell Lymphoma
DLBCL itself encompasses a biologically and clinically diverse set of diseases.
Although the WHO classification system defines more than a dozen subtypes, the were suggestive of significance (89) . Of these 153 SNPs, 123 mapped to the HLA region. The strongest HLA signal was at rs2523607, located near HLA-B (Table 4 ).
Following imputation of classical HLA alleles, only the HLA-B*08 allele and rs2523607 variant achieved genome-wide significance (p < 5 x 10 -8 ). These two markers are in LD (r 2 = 0.91) and after adjustment for the effect of HLA-B*08, the association at rs2523607 was attenuated; consistent with earlier observations, these data suggest that HLA-B*08 is the HLA allele most strongly associated with DLBCL.
Smaller GWAS identified weak associations with the class I SNP rs6457327 and class II SNP rs10484561, two SNPs that are strongly associated with FL (see below) (90, 91) and the association at rs10484561 was corroborated in the above GWAS meta-analysis (p = 1.5 x 10 -4 ). Two genotyping studies of DLBCL patients from The first GWAS to include samples from FL patients identified an association with SNPs within the HLA class I region. Disease risk was associated with rs6457327 and neighboring SNPs in a 26 kb block of sequence that overlaps the STG gene (C6orf15) and is near psoriasis susceptibility region 1 (PSORS1) (90) . This region is close to HLA-C and a later analysis showed that the 'A' allele at rs6457327 is associated with C*07:01 and B*07:02 (D' = 0.93 and 1.0, respectively); however, there is no evidence that these alleles account for the effect of the SNP.
Subsequent studies confirmed association with rs6457327 (97, 98) ; in addition, the risk allele 'A' and associated genotypes 'AA' and 'AC' were associated with an increased risk of, and, shorter time to, transformation as well as inferior OS (91, 97, 98) .
In Early case-control and family-based HLA typing studies did not identify consistent associations with HLA alleles, most probably because of small case numbers.
However, later studies provide support for some of the earlier findings, and the work of Dorak et al (1996) focused attention on DRB4 and associated haplotypes (103).
Machulla et al (2001) compared the frequency of HLA class I and II alleles in 101
cases and 157 controls using molecular and serological typing methods (104) . PCRbased typing revealed a striking increase in DRB4*01:03 alleles among cases (RR = 2.74, p = 0.0025); higher frequencies of DRB1*04:01, DQB1*03:02 and DPB1*03:01 and a lower frequency of DQB1*02:02 alleles were also detected. None of these differences remained significant after correction for multiple testing. The haplotype DRB1*04:01-DRB4*01:03 was also increased and CLL-specific LD was observed between these alleles. The association with DQB1*03:02 was thought to result from LD with DRB1*04:01-DRB4*01:03 on the ancestral haplotype HLA-Cw3-B62-DR4-DQ8, which is frequent in white populations. There was no evidence of LD between DPB1*03:01 and the other risk alleles.
In by far the largest study to date, Gragert SNPs in a region of HLA class II that includes the DQA1 and DRB5 genes (Figure 1 ).
Following conditional analyses of the five SNPs, only rs674313 retained significance thus suggesting that these SNPs are tagging the same locus (107) . Imputation of HLA alleles in this region was not performed. In contrast to the findings for cHL and FL described above, the strongest signals in GWAS were from non-HLA SNPs. At least 30 common risk variants have been identified thus far, with several in proximity to genes involved in apoptosis or telomere function (108, 109) . These data are consistent with the idea that co-inheritance of multiple low risk variants is likely to explain the heritability in CLL/SLL.
Summary and Conclusions
Recent GWAS and HLA typing studies provide consistent and reliable evidence linking specific HLA polymorphisms with subtypes of human lymphoma. Clustering of SNPs associated with cHL, FL and CLL within the HLA class II region is perhaps one of the most striking observations to emerge from these studies. However, associations within this region, which encompasses the HLA-DRA, DRB1 and DQB1 genes, are distinct for each of the three diseases ( Figure 1 ). Stratification of cHL cases by EBV status further demonstrates that the association with the DRA SNP rs6903608 is particular to EBV-cHL. In contrast, EBV+cHL is strongly associated with the class I allele HLA-A1*01, an allele first linked to HL over forty years ago.
Several alleles are associated with multiple lymphoma subtypes. Associations with DPB1*03:01 and DRB1*15:01 are described for FL and cHL; however, associations with FL are in the opposite direction from those reported for total cHL and EBV-cHL although the DRB1*15:01 association is in the same direction to that recently reported for EBV+cHL. Likewise, the HLA-A*02:01 allele is associated with increased risk of CLL but reduced risk of cHL. In contrast, the class II SNPs rs10484561 and rs2647012 are associated with increased risk of both FL and DLBCL, albeit with less significance for DLBCL, possibly implying that the DLBCL association is confined to a subset of DLBCLs with features more closely related to FL. Although the evidence for specific HLA associations with lymphoma subtypes is compelling, understanding the biology underlying these complex associations awaits further study.
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